V Square Quantitative Management LLC Has $858,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

V Square Quantitative Management LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,076 shares of the company’s stock after buying an additional 121 shares during the quarter. V Square Quantitative Management LLC’s holdings in IDEXX Laboratories were worth $858,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. CFC Planning Co LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $487,000. Vontobel Holding Ltd. lifted its holdings in shares of IDEXX Laboratories by 90.1% during the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after purchasing an additional 198,404 shares in the last quarter. Asset Management One Co. Ltd. lifted its holdings in shares of IDEXX Laboratories by 6.1% during the 4th quarter. Asset Management One Co. Ltd. now owns 52,844 shares of the company’s stock valued at $21,927,000 after purchasing an additional 3,057 shares in the last quarter. Avestar Capital LLC lifted its holdings in shares of IDEXX Laboratories by 5.9% during the 4th quarter. Avestar Capital LLC now owns 804 shares of the company’s stock valued at $332,000 after purchasing an additional 45 shares in the last quarter. Finally, Howard Bailey Securities LLC lifted its holdings in shares of IDEXX Laboratories by 22.1% during the 4th quarter. Howard Bailey Securities LLC now owns 1,094 shares of the company’s stock valued at $452,000 after purchasing an additional 198 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 3.3 %

NASDAQ:IDXX opened at $444.53 on Friday. The firm has a market capitalization of $36.40 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The stock’s 50 day moving average price is $430.77 and its two-hundred day moving average price is $453.31. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Finally, Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock valued at $6,161,276 in the last 90 days. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.